Welcome to our dedicated page for Vyne Therapeutics SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VYNE Therapeutics Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company developing BET inhibitor therapies for inflammatory and immune-mediated conditions. Form 8-K disclosures include quarterly results, clinical and regulatory updates for Repibresib gel and VYN202, and capital-structure information for VYNE common stock.
The filing record also covers stockholder meeting results, director and governance matters, material-event reports, registered security information, and Nasdaq continued-listing compliance disclosures, including minimum bid price notices and extension communications.
VYNE Therapeutics Inc. filed a Form 8-K noting that Yarrow Bioscience published an investor presentation tied to their planned reverse merger and concurrent financing. The presentation outlines Yarrow’s lead antibody YB-101 for Graves’ disease and thyroid eye disease, Phase 2 development plans starting in Q2 2026, and Fast Track status from the FDA for Graves’ disease. Yarrow reports about $200M raised to date, including an expected $100M pre-closing financing, with cash runway into 2028. Following the merger and financing, Yarrow stockholders are expected to own about 97% of the combined company and pre-merger VYNE holders about 3%, alongside an estimated cash dividend of $0.34–$0.38 per VYNE share before closing.
VYNE Therapeutics Inc. beneficial ownership disclosure: Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, each may be deemed to beneficially own 2,000,000 shares of common stock, representing 6.00% of the class as of March 31, 2026.
The filing states the shares are held by funds and separately managed accounts under Nantahala's control and that the reporting persons have shared voting and dispositive power over these 2,000,000 Shares.
VYNE Therapeutics reported Q1 2026 royalty revenue of $0.1 million, down from $0.2 million a year earlier, and cut research and development spending to $0.8 million from $6.1 million as it winds down its BET inhibitor programs ahead of a planned merger with Yarrow Bioscience.
Net loss narrowed to $3.6 million from $8.6 million, helped by lower R&D. Cash, cash equivalents and marketable securities totaled $24.9 million with no debt as of March 31, 2026, and stockholders’ equity was $24.6 million.
The company has agreed to merge with privately held Yarrow, which has already raised $100 million in Series A preferred stock and secured about $100 million in additional pre-closing financing commitments. Before closing, VYNE expects to pay a special cash dividend of roughly $14.5–$16.5 million in total to existing stockholders. Management believes current liquidity is sufficient through the anticipated Q3 2026 closing and for at least 12 months from the reporting date.
VYNE Therapeutics entered into a merger agreement to acquire Yarrow Bioscience, under which each share of Yarrow capital stock will convert into approximately 35.8455 shares of VYNE common stock (the "Exchange Ratio"). The transaction contemplates a private Yarrow Pre-Closing Financing of ~$100 million, an expected pre-closing Cash Dividend of approximately $14.5 million to $16.5 million, and an anticipated post-closing corporate name change to Yarrow Bioscience, Inc. Immediately after the Merger, VYNE securityholders are expected to own approximately 3.0% of the Combined Company on a fully-diluted basis and former Yarrow securityholders approximately 97.0%, subject to adjustment. VYNE has applied to list the Combined Company on Nasdaq under the symbol YARW; listing confirmation is a condition to closing. The VYNE board recommends that stockholders vote FOR the proposals required to complete the Merger.
VYNE Therapeutics Chief Financial Officer Zeronda Tyler reported an automatic tax-related share disposition. On the vesting of restricted stock units, 4,007 shares of common stock were withheld by the company at $0.5975 per share to cover tax obligations. After this non-market transaction, Tyler directly holds 99,788 shares of VYNE common stock.
VYNE Therapeutics Inc.'s Chief Scientific Officer Stuart Iain reported a routine tax-related share disposition. On the vesting of restricted stock units, 2,876 shares of common stock were withheld by the company to satisfy tax withholding requirements at an indicated value of $0.5975 per share. After this non-market transaction, he directly holds 112,363 common shares, so the withholding reflects only a small portion of his overall position.
VYNE Therapeutics Inc. chief legal officer Harsch Mutya reported a tax-related share disposition. On the vesting of restricted stock units, 4,007 shares of common stock were withheld by the company at $0.5975 per share to satisfy tax withholding requirements.
After this withholding, Mutya directly holds 121,898 shares of VYNE common stock. The transaction is classified as a tax-withholding disposition rather than an open-market sale.
VYNE Therapeutics President and CEO David Domzalski had 14,232 shares of Common Stock withheld on March 31, 2026 to cover tax obligations from vesting restricted stock units. This was a tax-withholding disposition at $0.5975 per share, and he continues to hold 401,976 shares directly.
VYNE Therapeutics Inc. proposes to issue VYNE common stock and pre-funded warrants as part of a merger with Yarrow Bioscience, Inc., pursuant to an Agreement and Plan of Merger and Reorganization dated December 17, 2025 (as amended). The filing sets an estimated exchange ratio of approximately 35.8667 VYNE shares per Yarrow share and describes a Yarrow pre-closing financing of approximately $100 million.
The proxy/prospectus explains treatment of options, assumed pre-funded warrants, a planned pre-closing cash dividend of about $14.5 million to $16.5 million, director and executive interests, support and lock-up agreements, Nasdaq initial listing expectations, and accounting as an in-substance reverse recapitalization (Yarrow as accounting acquirer). Proposals needing VYNE stockholder approval include issuance of shares under Nasdaq rules and a reverse stock split.
VYNE Therapeutics Inc. received an extension from Nasdaq to regain compliance with its minimum bid price listing rule. The company had previously failed to lift its common stock closing bid price back to at least $1.00 for 30 consecutive business days by March 10, 2026.
Nasdaq granted VYNE an additional 180 days, until September 7, 2026, to meet the $1.00 minimum bid price requirement. VYNE’s stock will continue trading on the Nasdaq Capital Market under the symbol “VYNE” during this period, and the company is considering options such as a potential reverse stock split to restore compliance.